Backing out of its mega deal was all AbbVie’s loss, as the pharmaceutical giant’s target, Shire, recently heralded record sales growth and a lofty vision for the next five years.

Shire’s top 10 products all posted double-digit sales growth in the third quarter, fueling an overall company sales increase of 32 percent and driving its 2014 earnings expectations up to nearly a 40 percent jump over last year.

“We have our hands full, but we also have our eyes open for opportunities in the marketplace,” CEO Flemming Ornskov said in a report by The Wall Street Journal.

He intends to double Shire’s sales and hit the $10 billion milestone by 2020, and that’s good news for the U.S. operations base in Wayne.

Read more about Shire’s impressive quarter of growth and Ornskov’s plans for the future, particularly in the rare disease drug market, in The Wall Street Journal here.